Hepato Care Products

Hepato Care Products

Viral hepatitis, caused by hepatitis viruses A through E, is a significant public health problem in India. An estimated 40 million people in India have chronic hepatitis B infection, constituting approximately 11% of the estimated global burden. Hepatitis C affects about 12 million patients in India. Both of these blood-borne infections have high risk of chronicity with progression to advanced liver disease and are associated with development of hepatocellular carcinoma, a type of liver cancer, underscoring the need for increased access to high quality, affordable and effective therapy in India.

Mylan India launched its Hepato Care division in January 2015 to respond to this public health concern and help meet the unmet medical needs of the patients in India who do not currently have access to critical medicines. 

  • MyHep™

    Sofosbuvir Tablets
    Strength: 400mg
    Primary Pack: HDPE bottle containing 28 film coated tablets
  • Sovaldi®

    Sofosbuvir Tablets
    Strength: 400 mg
    Primary Pack: HDPE bottle containing 28 film coated tablets

    Link to Prescribing Information Including all WARNINGS

  • Viread®

    Tenofovir Disoproxil Fumarate Tablets IP
    Strength: 300 mg
    Primary Pack: HDPE bottle containing 30 film coated tablets
    Tenofovir Disoproxil Fumarate

    Link to Prescribing Information Including all WARNINGS

The product database is intended as a general reference source only and is not a substitute for qualified medical care from a licensed physician.

Viread and Sovaldi are registered trademarks of Gilead Sciences

Expanding Access
to Hepatitis Treatments

Mylan is working with partners like Gilead Sciences to help expand access to innovative hepatitis medicines in India.

  • Questions?

    Get more information on our products, services and Mylan Global Center locations.

    Contact Us

  • Business Opportunities

    Do you have an opportunity or a collaboration idea?

    Partner with us